Dopamine agonists are commonly used in the medical treatment of prolactinomas. Bromocriptine has been the most widely used ergot derivative for two decades. Its oral administration, at a daily dose of 2.5-7.5 mg, restored normal gonadal function and normoprolactinemia in about 80% of patients (1, 2) . Nevertheless, a subset of patients could not achieve normal PRL levels or resume normal gonadal function despite [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] mg/ day bromocriptine for at least 6 months. Subsequently, these prolactinomas were considered to be resistant to bromocriptine. The percentage of bromocriptineresistant prolactinoma patients reported in the literature varies between 5 and 17% according to the series (1) (2) (3) (4) (5) .
In such resistant patients, different groups (6-11 ) tested the eventual efficacy of the non-ergot dopamine agonist, quinagolide (Norprolac, Sandoz, Basel, Switzer¬ land) (12) . The analysis of these data comparing bromocriptine versus quinagolide afforded somewhat variable results, mainly due to the small number of patients included and followed for relatively short periods of time. The aim of this study was (Fig. 1A) confirmed the long-term efficacy of the quinagolide treatment in 11/12 patients (patients [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . In contrast, a secondary rise of PRL levels without evidence of tumor growth occurred at 1 year of treatment in patient 12 (Fig. IB) (Fig. 2A) (Fig. 3) The availability of quinagolide (12), a high-affinity and selective dopamine D2 receptor agonist, prompted different groups to substitute this new drug for bromocriptine in order to test its possible efficacy in prolactinomas resistant to bromocriptine (6) (7) (8) (9) (10) (11) . From these data, the replacement of bromocriptine (15- 
